Department of Medical Oncology, Ordu University School of Medicine, Ordu, Turkey.
Department of Medical Oncology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey.
Sci Rep. 2024 Oct 9;14(1):23556. doi: 10.1038/s41598-024-75293-5.
The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1-3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2-0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1-0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied.
评估新辅助治疗中 Her2 水平影响的研究数据存在矛盾。本研究旨在评估早期三阴性乳腺癌（TNBC）中 Her2 状态的预后影响。本研究回顾性分析了接受新辅助化疗（NAC）和手术治疗的 TNBC 患者。本研究的主要目的是分析 Her2 状态（Her2-0 和 Her2-低）对病理完全缓解（pCR）的影响。次要目标是无病生存（DFS）和总生存（OS）。评估了 620 例女性三阴性乳腺癌患者。427 例（68.9%）患者 Her2-0，193 例（31.1%）患者 Her2-低。Her2-0 组和 Her2-低组的 pCR 率相似（33.0%比 27.5%，p=0.098）。尽管 Her2-0 组的 DFS 更好（106 比 50 个月，p=0.002），但多变量分析显示其 HR 为 0.74（p=0.06）。此外，OS 相似（131 比 105 个月，p=0.13），HR 为 0.88（p=0.61）。多变量分析中；存在 LVI（HR：2.2（95%CI 1.1-3.5）p=0.001）、临床分期 T1/T2（HR：0.39（95%CI 0.2-0.6）p<0.001）和淋巴结阴性（HR：0.35（95%CI 0.1-0.9）p=0.03）是 OS 的独立因素。尽管存在病理和临床差异，但 Her2-0 和 Her2-低 TNBC 患者的 pCR、DFS 和 OS 相似。新辅助治疗中 TNBC Her2 状态的重要性需要进一步研究。
